Nothing Special   »   [go: up one dir, main page]

AU2002361682A1 - Innate immune system-directed vaccines - Google Patents

Innate immune system-directed vaccines

Info

Publication number
AU2002361682A1
AU2002361682A1 AU2002361682A AU2002361682A AU2002361682A1 AU 2002361682 A1 AU2002361682 A1 AU 2002361682A1 AU 2002361682 A AU2002361682 A AU 2002361682A AU 2002361682 A AU2002361682 A AU 2002361682A AU 2002361682 A1 AU2002361682 A1 AU 2002361682A1
Authority
AU
Australia
Prior art keywords
immune system
innate immune
directed vaccines
vaccines
directed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002361682A
Other versions
AU2002361682A8 (en
Inventor
Elizabeth Kopp
Ruslan Medzhitov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of AU2002361682A1 publication Critical patent/AU2002361682A1/en
Publication of AU2002361682A8 publication Critical patent/AU2002361682A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2002361682A 2001-12-14 2002-12-13 Innate immune system-directed vaccines Abandoned AU2002361682A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34017401P 2001-12-14 2001-12-14
US60/340,174 2001-12-14
PCT/US2002/040046 WO2003051305A2 (en) 2001-12-14 2002-12-13 Innate immune system-directed vaccines

Publications (2)

Publication Number Publication Date
AU2002361682A1 true AU2002361682A1 (en) 2003-06-30
AU2002361682A8 AU2002361682A8 (en) 2003-06-30

Family

ID=23332201

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002361682A Abandoned AU2002361682A1 (en) 2001-12-14 2002-12-13 Innate immune system-directed vaccines

Country Status (2)

Country Link
AU (1) AU2002361682A1 (en)
WO (1) WO2003051305A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2555253A1 (en) * 2004-02-06 2005-08-25 Yale University Compositions of pamps and listeria monocytogenes and methods of use
JP5191740B2 (en) * 2005-01-28 2013-05-08 ガレンバイオ、インコーポレイテッド Immunologically active composition
WO2007103322A2 (en) 2006-03-07 2007-09-13 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
EP2112158B1 (en) * 2007-04-20 2011-10-19 F. Hoffmann-La Roche AG Detection of primary infections with pathogens
WO2009082440A2 (en) * 2007-12-18 2009-07-02 Vaxinnate Corporation Compositions of toll-like receptor agonists and malaria antigens and methods of use
WO2009128950A2 (en) 2008-04-18 2009-10-22 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
SI22883A (en) * 2008-10-28 2010-04-30 Kemijski inštitut Vaccines that unite antigen and toll-like receptors
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
EP2921178A1 (en) 2014-03-19 2015-09-23 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Toll-like receptor 2 agonists and vaccines and uses thereof
JP2019514939A (en) 2016-04-26 2019-06-06 クー バイオロジックス インコーポレイテッドＱｕ Ｂｉｏｌｏｇｉｃｓ Ｉｎｃ． Therapeutic induction of innate immune response in target tissues

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1165779A1 (en) * 1999-04-01 2002-01-02 The Governing Council Of The University Of Toronto A presenilin associated membrane protein and uses thereof
US20020061312A1 (en) * 2000-07-31 2002-05-23 Ruslan Medzhitov Innate immune system-directed vaccines
CA2417136A1 (en) * 2000-09-01 2002-03-07 The Governing Council Of The University Of Toronto Proteins related to schizophrenia and uses thereof

Also Published As

Publication number Publication date
WO2003051305A3 (en) 2004-04-29
WO2003051305A2 (en) 2003-06-26
AU2002361682A8 (en) 2003-06-30

Similar Documents

Publication Publication Date Title
AU8640501A (en) Innate immune system-directed vaccines
AU2002336760A1 (en) Mutable vaccines
HUP0402259A3 (en) Vaccines
GB0130215D0 (en) Vaccine
AU2002254558A1 (en) Novel vaccine
IL157498A0 (en) Vaccine
GB0121171D0 (en) Vaccine
AU2002361682A1 (en) Innate immune system-directed vaccines
PL363181A1 (en) Modified interferon alpha with reduced immunogenicity
AU2002334631A1 (en) Immune response associated proteins
AU2003237701A1 (en) Vaccines
AU2002304165A1 (en) Polynucleotide vaccine
GB0105238D0 (en) Vaccines
AU2002355913A1 (en) Anti-tumor vaccines
AU2002251271A1 (en) Stimulation of the immune system
AU2002302785A1 (en) Vaccines
AU2002362494A1 (en) Tumor-peptide antigens from the human prdi-bf1-protein
AU2001255380A1 (en) Human interferon, zinf2
AUPR440001A0 (en) Vaccine
AU2002337263A1 (en) Anti-coronavirus vaccine
AUPR788601A0 (en) Fasciola vaccine
AU2002253048A1 (en) Novel vaccine
CA91810S (en) Airplane
GB0115496D0 (en) Vaccine
GB0106589D0 (en) Vaccine

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase